Saisei Mirai Clinic
Title: Clinical experience of colostrum derived protein against solid cancer
Biography: Shinichiro Akiyama
Recently immunotherapy has become an attractive new strategy in the treatment of cancer, boosting the patient's own immune system to eradicate cancer cells. The toxicities of immunotherapy for cancer are as diverse as the type of treatments that have been devised. Immune surveillance by macrophage is critical for the immune integrity since invertebrates has evolved and is imposed through an intricate armory of functions that can infiltrate into tumors tissue. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum derived vitamin D binding protein has shown high macrophage phagocytic activity as well as anti-tumor activities. Oral colostrum MAF stimulates macrophage whereas its precious mechanism has not yet been understood. It is administered orally in an acid-resistant enteric capsule to activate macrophages in the gut-associated lymphoid tissue and as a powder in the mouth to activate macrophages in the lymphoid tissue of the Waldeyer's tonsillar ring. In terms of practical clinical use, oral colostrum MAF has certain advantages over MAF produced from serum because it is derived from bovine colostrum and it is administered orally and sub-lingually instead of injection. We propose that oral colostrum MAF and MAF produced from serum could demonstrate a greater immunotherapeutic activity than that of serum MAF alone. We have also treated cancer patients with oral colostrum MAF in combination with cancer gene therapy and/or NK cell therapy so as to induce higher potential benefit of solid cancer therapy.